Abstract
PURPOSE OF REVIEW: This review focuses on combination drug treatment for acromegaly patients, including novel concepts and experimental therapies, with an emphasis on the author's personal experience. RECENT FINDINGS: A review of published clinical studies demonstrates that combination therapy; somatostatin receptor ligands and dopamine agonists, somatostatin receptor ligands and pegvisomant, or cabergoline and pegvisomant could provide significant additive biochemical control of acromegaly in patients inadequately controlled with conventional somatostatin receptor ligand therapy. SUMMARY: Advances in combination medical therapy have opened up new perspectives for acromegaly patients who are poorly, or nonresponsive to, presently available single drug therapies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 321-329 |
| Number of pages | 9 |
| Journal | Current Opinion in Endocrinology, Diabetes and Obesity |
| Volume | 20 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 2013 |
Keywords
- acromegaly
- combination therapy
- dopamine agonists
- growth hormone receptor antagonist
- somatostatin receptor ligands
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Endocrinology
- Nutrition and Dietetics